

Tarik Belhocine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/39444460/publications.pdf>

Version: 2024-02-01

40
papers

1,925
citations

471509

17
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

1839
citing authors

#	ARTICLE	IF	CITATIONS
1	99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2083-2097.	6.4	37
2	Annexin A5 Imaging: An Academic Research " Clinical Trials and Theses. <i>Current Molecular Imaging</i> , 2014, 3, 52-63.	0.7	1
3	Added-value of SPECT/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 182-93.	1.0	13
4	18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 45-55.	3.9	139
5	Differentiated Thyroid Cancer With Epiphora. <i>Clinical Nuclear Medicine</i> , 2011, 36, 1149-1152.	1.3	18
6	Transbilayer phospholipids molecular imaging. <i>EJNMMI Research</i> , 2011, 1, 17.	2.5	13
7	SPECT/CT imaging of the lumbar spine in chronic low back pain: a case report. <i>Chiropractic & Manual Therapies</i> , 2011, 19, 2.	1.5	12
8	Small field-of-view cardiac SPECT can be implemented on hybrid SPECT/CT platforms where data acquisition and reconstruction are guided by CT. <i>Nuclear Medicine Communications</i> , 2009, 30, 718-726.	1.1	2
9	Accuracy of quantitative reconstructions in SPECT/CT imaging. <i>Physics in Medicine and Biology</i> , 2008, 53, 4595-4604.	3.0	103
10	Complementary Roles of Low-dose SPECT-CT and High-resolution Volume CT for Detection of Coronary Artery Disease. <i>Clinical Nuclear Medicine</i> , 2008, 33, 285-287.	1.3	6
11	18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology. , 2008, , 193-200.		2
12	How Useful is an Integrated SPECT/CT in Clinical Setting and Research?: Evaluation of a Low Radiation Dose 4 Slice System. <i>The Open Medical Imaging Journal</i> , 2008, 2, 80-108.	0.8	5
13	Detection of 99mTc-sestamibi uptake in brown adipose tissue with SPECT-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 149-149.	6.4	19
14	Novel Imaging Techniques in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 253-283.	1.5	18
15	18FDG PET in oncology: The best and the worst (Review). <i>International Journal of Oncology</i> , 2006, 28, 1249.	3.3	22
16	Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. <i>Oncology Reports</i> , 2006, 16, 347.	2.6	8
17	The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research. <i>Current Clinical Pharmacology</i> , 2006, 1, 129-137.	0.6	11
18	Role of nuclear medicine in the management of cutaneous malignant melanoma. <i>Journal of Nuclear Medicine</i> , 2006, 47, 957-67.	5.0	108

#	ARTICLE	IF	CITATIONS
19	A plea for the elective inclusion of the brain in routine whole-body FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 251-256.	6.4	3
20	Metabolic Monitoring of Chemosensitivity with ¹⁸ F-FDG PET. , 2005, 111, 417-440.		7
21	^{99m} Tc-Annexin A5 Uptake and Imaging to Monitor Chemosensitivity. , 2005, 111, 363-380.		12
22	The right place of ¹⁸ F-FDG PET for the diagnosis of giant cell arteritis—a response to the article of Brodmann et al.. <i>British Journal of Rheumatology</i> , 2004, 43, 675-676.	2.3	2
23	The Imaging of Apoptosis with the Radiolabeled annexin V: Optimal Timing for Clinical Feasibility. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 23-32.	1.9	47
24	Whole-body ¹⁸ F-FDG PET plus pelvic MRI in the pre-treatment assessment of cervical cancers: an alternative to the FIGO clinical staging. <i>Gynecological Surgery</i> , 2004, 1, 95-100.	0.9	1
25	¹⁸ F-FDG imaging of giant cell arteritis: usefulness of whole-body plus brain PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1055-6.	6.4	5
26	Nuclear Medicine in the Era of Genomics and Proteomics: Lessons from Annexin V. <i>Journal of Proteome Research</i> , 2004, 3, 345-349.	3.7	20
27	Evaluation of Pleural Disease With ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Imaging. <i>Chest</i> , 2004, 125, 489-493.	0.8	154
28	¹⁸ F-FDG PET imaging in posttherapy monitoring of cervical cancers: from diagnosis to prognosis. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1602-4.	5.0	13
29	In Vivo Imaging of Chemotherapy-Induced Apoptosis in Human Cancers. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 525-529.	3.8	32
30	Imaging of large vessel vasculitis with ¹⁸ F-FDG PET: illusion or reality? A critical review of the literature data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1305-1313.	6.4	174
31	Staging of primary cervical cancers: the role of nuclear medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 275-284.	4.4	16
32	Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. <i>Annals of Oncology</i> , 2003, 14, 123-130.	1.2	191
33	Staging of Regional Nodes in AJCC Stage I and II Melanoma: ¹⁸ F-FDG PET Imaging versus Sentinel Node Detection. <i>Oncologist</i> , 2002, 7, 271-278.	3.7	92
34	Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. <i>Nuclear Medicine Communications</i> , 2002, 23, 727-734.	1.1	125
35	Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma. <i>Dermatology</i> , 2002, 204, 355-361.	2.1	8
36	Usefulness of ¹⁸ F-FDG PET in the post-therapy surveillance of endometrial carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1132-1139.	6.4	127

#	ARTICLE	IF	CITATIONS
37	Contribution of Whole-Body 18FDG PET Imaging in the Management of Cervical Cancer. Gynecologic Oncology, 2002, 87, 90-97.	1.4	124
38	Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clinical Cancer Research, 2002, 8, 2766-74.	7.0	226
39	A Case of Cerebral Metastases of Unknown Origin. Clinical Nuclear Medicine, 2001, 26, 793.	1.3	1
40	Typical Appearance of Mesothelioma on an F-18 FDG Positron Emission Tomograph. Clinical Nuclear Medicine, 2000, 25, 636.	1.3	8